目的 探讨乙型肝炎病毒(hepatitis B virus,HBV)高病毒载量孕妇母婴传播阻断失败的相关危险因素,为临床优化防控方案提供依据。方法 采用回顾性病例对照研究设计,选取2021年1月—2024年8月在山西省运城市中心医院分娩的HBV高病毒载量(HBV DNA>106 IU/mL)孕妇作为研究对象。根据新生儿12月龄时HBV感染状态分为阻断失败组(阻断失败,n=87)和阻断成功组(阻断成功,n=261)。所有孕妇均被提供或建议接受基于指南的联合阻断方案,包括孕晚期口服替诺福韦酯、新生儿注射乙型肝炎免疫球蛋白(hepatitis B immunoglobulin,HBIG)及乙肝疫苗接种。收集并比较两组的人口学特征、病毒学指标[乙型肝炎e抗原(hepatitis B e antigen,HBeAg)、丙氨酸氨基转移酶(alanine aminotransferase,ALT)、HBV DNA]、干预措施及新生儿出生结局,采用单因素及多因素Logistic回归分析阻断失败的独立危险因素。结果 阻断失败组孕妇HBeAg阳性率(95.40% vs 21.07%)、分娩前HBV DNA水平(≥1.0×107 IU/mL,77.01% vs 43.30%)及脐带血HBV DNA阳性率(80.50% vs 0.00%)均显著高于阻断成功组,抗病毒治疗覆盖率(40.23% vs 86.21%)显著低于阻断成功组(P<0.001)。在接受抗病毒治疗的亚组中,阻断失败组治疗后应答不佳率(65.71% vs 15.11%)、新生儿疫苗首剂接种>12小时及HBIG注射>6小时比例显著高于阻断成功组(均P<0.001)。多因素分析显示,分娩前HBV DNA≥1.0×107 IU/mL,其调整后比值比(adjusted odds ratio,aOR)为8.17(95% CI:3.66~18.22)、脐带血HBV DNA阳性(aOR=94.65,95% CI:34.08~262.85)、治疗持续时间不足(aOR=4.48,95% CI:1.85~10.82)及抗病毒治疗应答不佳(aOR=4.95,95% CI:2.09~11.73)是母婴阻断失败的独立危险因素(均P<0.001)。结论 HBV高病毒载量孕妇的母婴阻断效果受母体高病毒载量、HBeAg阳性、抗病毒治疗覆盖率低及治疗应答不佳等因素显著影响。临床应加强病毒学监测、规范抗病毒治疗并确保新生儿免疫及时性,以降低阻断失败风险。
Abstract
Objective To explore the risk factors associated with failure of mother-to-child transmission (MTCT) blockade in pregnant women with a high hepatitis B virus (HBV) viral load, and to provide evidence for optimizing clinical prevention and control strategies. Methods A retrospective case-control study was conducted, involving pregnant women with a high HBV viral load (HBV DNA>107 IU/mL) who delivered at Yuncheng Central Hospital, Shanxi Province, China, between January 2021 and August 2024. Based on the HBV infection status of the neonates at 12 months of age, the subjects were stratified into the prophylaxis failure group (failure, n=87) and the prophylaxis success group (success, n=261). All pregnant women were offered or advised to receive a guideline-based combined prophylaxis regimen, including oral tenofovir disoproxil in the third trimester, neonatal HBIG injection, and hepatitis B vaccination. Demographic characteristics, virological markers (HBeAg, ALT, HBV DNA), interventions, and neonatal birth outcomes were collected and compared between the two groups. Univariate and multivariate logistic regression analyses were employed to identify independent risk factors for prophylactic failure. Results The prophylaxis failure group showed significantly higher rates of maternal HBeAg positivity (95.40% vs 21.07%), pre-delivery HBV DNA levels (≥1.0×107 IU/mL, 77.01% vs 43.30%), and umbilical cord blood HBV DNA positivity (80.50% vs 0.00%), along with a significantly lower antiviral therapy coverage rate (40.23% vs 86.21%) compared with the prophylaxis success group (all P<0.001). Within the subgroup receiving antiviral therapy, the prophylaxis failure group had a significantly higher rate of suboptimal antiviral response (65.71% vs 15.11%) and higher proportions of neonates receiving the first vaccine dose>12 hours after birth and HBIG injection>6 hours after birth than the prophylaxis success group (all P<0.001). Multivariate analysis revealed that pre-delivery HBV DNA≥1.0×107 IU/mL (aOR=8.17, 95% CI: 3.66-18.22), positive umbilical cord blood HBV DNA (aOR=94.65, 95% CI: 34.08-262.85), insufficient duration of antiviral therapy (aOR=4.48, 95% CI: 1.85-10.82), and suboptimal antiviral response (aOR=4.95, 95% CI: 2.09-11.73) were independent risk factors for mother-to-child transmission prophylaxis failure (all P<0.001). Conclusion The effectiveness of MTCT blockade in pregnant women with high HBV viral load is significantly influenced by high maternal viral load, HBeAg positivity, low antiviral treatment coverage, and suboptimal treatment response. Clinical practice should emphasize enhanced virological monitoring, standardized antiviral therapy, and ensuring the timeliness of neonatal immunoprophylaxis to reduce the risk of blockade failure.
关键词
乙型肝炎病毒 /
高病毒载量 /
母婴传播 /
阻断失败 /
危险因素 /
抗病毒治疗 /
脐带血HBV DNA
Key words
hepatitis B virus /
high viral load /
mother-to-child transmission /
blockade failure /
risk factors /
antiviral therapy /
umbilical cord blood HBV DNA
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] CAO G, LIU J, LIU M.Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study[J]. Chin Med J, 2022, 135(17): 2049-2055.
[2] 李维丹, 石小霞, 何竞月. 妊娠期糖尿病合并HBV感染与妊娠结局研究进展[J]. 病毒学报, 2025, 41(1): 257-263.
[3] 潘雪梅. 替诺福韦用于妊娠晚期HBV高载量母婴阻断的临床效果分析[J]. 北方药学, 2025, 22(1): 28-30.
[4] PAN CQ, DUAN Z, DAI E, et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374(24): 2324-2334.
[5] SHENG QJ, WANG SJ, WU YY, et al.Hepatitis B virus serosurvey and awareness of mother-to-child transmission among pregnant women in Shenyang, China: an observational study[J]. Medicine, 2018, 97(22): e10931.
[6] 肖跃飞, 童安荣, 王耀光, 等. 乙型肝炎病毒相关性肾炎中西医诊断与治疗[J]. 中国中西医结合肾病杂志, 2025, 26(3): 279-281.
[7] 徐陈瑜, 徐娟. 妊娠合并乙型肝炎病毒感染研究进展[J]. 中国临床研究, 2021, 34(11): 1561-1564.
[8] 杨晓蕾, 池振静, 孙逸冕, 等. 替诺福韦联合主被动免疫阻断高血清乙型肝炎病毒载量孕妇母婴传播效果研究[J]. 实用肝脏病杂志, 2023, 26(2): 177-180.
[9] 李光晨, 索淑一, 韩白乙拉. 替诺福韦酯、替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播的疗效[C]//全国疑难及重症肝病攻关协作组, 北京肝胆相照公益基金会, 北京医药科学技术发展协会. 第12届全国疑难及重症肝病大会论文汇编. 大连, 2023: 241.
[10] GHANY MG, BUTI M, LAMPERTICO P, et al.Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference[J]. Hepatology, 2023, 78(5): 1654-1673.
[11] 张伟, 池频频, 王富珍, 等. 孕期抗病毒治疗结合标准阻断措施对乙型肝炎高病毒载量孕妇所生婴儿母婴传播阻断的影响[J]. 中国疫苗和免疫, 2020, 26(2): 146-150.
[12] DING Y, CAO L, ZHU L, et al.Efficacy and safety of tenofovir alafenamide fumarate for preventing mother to child transmission of hepatitis B virus: a national cohort study[J]. Aliment Pharmacol Ther, 2020, 52(8): 1377-1386.
[13] 樊慧杰, 姜国伟. 替诺福韦酯治疗阻断妊娠晚期HBV携带孕妇病毒母婴传播的疗效和安全性评价[J]. 肝脏, 2024, 29(10): 1247-1250.
[14] 梁艳, 李颖, 马仲丽, 等. HBsAg阳性孕产妇LTA基因多态性与HBV母婴传播的关联性[J]. 中华医院感染学杂志, 2022, 32(1): 130-134.
[15] 王翠敏, 韩国荣, 江红秀, 等. 不同联合免疫策略对乙型肝炎病毒高载量孕妇所生婴儿抗-HBs水平的影响[J]. 中华肝脏病杂志, 2015, 23(7): 5.
[16] WEDEMEYER H, SCHÖNEWEIS K, BOGOMOLOV P, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection: a multicentre, randomised, parallel-group, open-label, phase 2 trial[J]. Lancet Infect Dis, 2023, 23(1): 117-129.
[17] ZENG QL, YU ZJ, JI F, et al.Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study[J]. Clin Infect Dis, 2021, 73(9): e3324-e3332.
[18] KARAHODA R, CECKOVA M, STAUD F.The inhibitory effect of antiretroviral drugs on the L-carnitine uptake in human placenta[J]. Toxicol Appl Pharmacol, 2019, 368: 18-25.
[19] 郭美静. 药物阻断乙肝病毒在母婴间传播的动力学模型的研究[D]. 哈尔滨: 哈尔滨理工大学, 2019.
[20] LIU X, CHEN C, JIANG D, et al.Comparison of HBV-DNA and HBeAg as antiviral therapeutic indicators among HBV-infected pregnant women: a systematic review and meta-analysis[J]. Ann Palliat Med, 2021, 10(9): 9362-9371.
[21] CUI F, WOODRING J, CHAN P, et al.Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China[J]. Int J Epidemiol, 2018, 47(5): 1529-1537.
基金
山西省卫生健康委科研课题计划“辅助生殖技术受孕与自然受孕双胎妊娠对母儿结局的影响”(2019163)